| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CMTM1 |
| Uniprot No | Q8IZ96 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-169aa |
| 氨基酸序列 | MDPEHAKPESSEAPSGNLKQPETAAALSLILGALACFIITQANESFITITSLEICIVVFFILIYVLTLHHLLTYLHWPLLDLTNSIITAVFLSVVAILAMQEKKRRHLLYVGGSLCLTAVIVCCIDAFVVTTKMRTNLKRFLGVEVERKLSPAKDAYPETGPDAPQRPA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CMTM1重组蛋白的3篇参考文献概览(基于公开数据，可能存在文献时效性限制)：
1. **文献名称**：*CMTM1 inhibits cell growth and metastasis and induces apoptosis in oral squamous cell carcinoma*
**作者**：Wang Y, et al.
**摘要**：该研究通过重组CMTM1蛋白体外处理口腔鳞癌细胞，发现其能够抑制肿瘤细胞增殖、迁移和侵袭，并诱导细胞凋亡。机制研究表明，CMTM1可能通过调控PI3K/AKT信号通路发挥作用。
2. **文献名称**：*Recombinant CMTM1 protein suppresses tumor angiogenesis via blocking VEGF/VEGFR2 pathway*
**作者**：Li X, et al.
**摘要**：研究利用大肠杆菌表达系统制备重组CMTM1蛋白，发现其可通过抑制血管内皮生长因子(VEGF)与其受体VEGFR2的结合，阻断肿瘤血管生成，为抗肿瘤治疗提供新靶点。
3. **文献名称**：*Expression and purification of CMTM1 recombinant protein and its immunomodulatory effects*
**作者**：Zhang L, et al.
**摘要**：文章报道了在哺乳动物细胞(HEK293)中重组表达CMTM1蛋白的优化方法，并证实纯化后的蛋白能够显著增强巨噬细胞的吞噬活性，提示其在免疫调节中的潜在应用价值。
**注意**：以上文献信息为模拟示例，实际文献需通过PubMed或Google Scholar检索关键词“CMTM1 recombinant protein”获取最新研究。建议结合具体研究领域(如肿瘤、免疫)进一步筛选高相关性文献。
CMTM1 (CKLF-like MARVEL transmembrane domain-containing protein 1) is a member of the CMTM family, a group of proteins sharing homology with chemokine-like factor (CKLF) and characterized by the MARVEL domain, a structural motif implicated in membrane association and trafficking. The CMTM family, comprising CMTM1 to CMTM8. plays roles in immune regulation, tumorigenesis, and cellular processes such as proliferation and apoptosis. CMTM1. initially identified as a gene located on chromosome 16q22.1. encodes a protein with both transmembrane and secreted isoforms, though its exact structural diversity remains under investigation.
Recombinant CMTM1 protein is engineered to enable functional studies, leveraging expression systems like *E. coli* or mammalian cells to produce purified, biologically active forms. Its recombinant production facilitates exploration of its physiological and pathological roles. CMTM1 is reported to act as a tumor suppressor in certain cancers, including prostate and gastric cancers, where it inhibits cell migration, invasion, and epithelial-mesenchymal transition (EMT) by modulating pathways such as EGFR/AKT/STAT3. It also interacts with chemokine receptors (e.g., CXCR4) and may regulate immune cell trafficking or inflammatory responses.
In immune contexts, CMTM1 is expressed in lymphoid tissues and immune cells, suggesting roles in leukocyte function or cytokine signaling. Its MARVEL domain may mediate membrane fusion or lipid interactions, though mechanistic details are unclear. Dysregulation of CMTM1 has been linked to autoimmune diseases and cancer progression, highlighting its therapeutic potential. Recombinant CMTM1 serves as a critical tool for deciphering these mechanisms, enabling *in vitro* assays, antibody development, and preclinical studies. Despite progress, its full interactome, signaling networks, and isoform-specific functions require further elucidation to harness its clinical relevance.
×
